We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Myriad Genetics, Inc. (MYGN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 20.50 |
| Open | 20.34 |
| Bid | 19.51 x 100 |
| Ask | 19.58 x 100 |
| Day's Range | 19.39 - 20.40 |
| 52 Week Range | 13.82 - 24.21 |
| Volume | |
| Avg. Volume | 622,504 |
| Market Cap | 1.757B |
| Beta (5Y Monthly) | 1.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.18 |
| Earnings Date | May 01, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.36 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MYGN
Related Research
- Myriad Genetics, Inc.MYGN: Raising target price to $22.00MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat3 days agoArgus Research
ZacksMyriad Genetics (MYGN) Announces Favorable Research Results
Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.
ZacksHere's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
GlobeNewswireMyriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight testSALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test. “We are encouraged by the initial results of
ZacksNovavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound?
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksWhy Is Myriad (MYGN) Down 1% Since Last Earnings Report?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksMyriad Genetics (MYGN) Wins Foundational Patent for MRD Assay
Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.
- GlobeNewswire
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.
- GlobeNewswire
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination. U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040.
ZacksMyriad Genetics (MYGN) to Evaluate MRD Testing With New Pact
Myriad Genetics' (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential for a pan-cancer investigation.
ZacksWhy This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Morningstar Rating
Rating
Fair Value
Economic Moat
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| INCY Incyte Corporation | |||
| ALKS Alkermes plc | |||
| NBIX Neurocrine Biosciences, Inc. | |||
| LGND Ligand Pharmaceuticals Incorporated | |||
| UTHR United Therapeutics Corporation |
Similar to MYGN
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| SHC Sotera Health Company | |||
| QGEN Qiagen N.V. | |||
| CRL Charles River Laboratories International, Inc. | |||
| DGX Quest Diagnostics Incorporated | |||
| RVTY Revvity, Inc. |
Analyst Price Targets (11)
Upgrades & Downgrades
| Maintains | Goldman Sachs: Buy to Buy | 1/30/2024 | |
| Maintains | Goldman Sachs: Buy to Buy | 1/29/2024 | |
| Initiated | Piper Sandler: to Neutral | 12/21/2023 | |
| Initiated | Wells Fargo: to Equal-Weight | 12/19/2023 | |
| Initiated | Guggenheim: to Buy | 12/14/2023 | |
| Initiated | Wolfe Research: to Outperform | 12/13/2023 |
Company Profile
322 North 2200 West
Salt Lake City, UT 84116
United States
801 584 3600
https://www.myriad.com
Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 2,700
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
